Advances in multi-omics technologies for assisting therapeutic strategies in glioma.
The high heterogeneity and resistance of glioma present significant challenges in clinical treatment. The rapid development of multi-omics technologies has greatly advanced the understanding of the molecular mechanisms, resistance characteristics, and potential new drug targets in glioma. Building o...
| Publicado en: | Chinese Journal of Contemporary Neurology & Neurosurgery Vol. 25; no. 2; pp. 136 - 144 |
|---|---|
| Autores principales: | , |
| Formato: | review Journal Article |
| Publicado: |
Chinese Journal of Contemporary Neurology & Neurosurgery
Feb2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=184219193&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 184219193 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16726731 FDQ6 jtl: Chinese Journal of Contemporary Neurology & Neurosurgery issn: 16726731 maglogo: N pubinfo: dt: Feb2025 vid: 25 iid: 2 pid: 80951 pub: Chinese Journal of Contemporary Neurology & Neurosurgery artinfo: ui: 184219193 184219193 184219193 10.3969/j.issn.1672-6731.2025.02.006 184219193 ppf: 136 ppct: 8 formats: fmt: @attributes: type: P tig: atl: Advances in multi-omics technologies for assisting therapeutic strategies in glioma. aug: au: SUN Yi-shuo ZHANG Wei affil: Department of Neurosurgery, Beijing Tirantean Hospital, Capital Medical University, Beijing 100070, China sug: subj: Glioma Therapy Multiomics Drug Development Clinical Trials Mutation Gene Expression Proteins Physiology Metabolic Reprogramming Individualized Medicine Drug Evaluation, Preclinical Precision Medicine Patient Centered Care ab: The high heterogeneity and resistance of glioma present significant challenges in clinical treatment. The rapid development of multi-omics technologies has greatly advanced the understanding of the molecular mechanisms, resistance characteristics, and potential new drug targets in glioma. Building on this, multi - omics data is now being used for drug screening, mechanism exploration, and clinical trial guidance, thereby accelerating the translation of novel therapies and precision medicine strategies into clinical applications for the treatment of glioma. This review focuses on the latest advancements in the application of multi-omics technologies in glioma drug research and development, highlighting how insights into genetic mutations, gene expression, protein functions, and metabolic reprogramming can aid in understanding the molecular mechanisms, resistance, and complexity of the tumor microenvironment. Furthermore, it provides critical support for the identification of new drug targets, the development of personalized treatment plans, and drug screening, thus advancing the field of personalized and precision medicine in the treatment of glioma. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: Chinese refInfo: holdings: @attributes: islocal: N |
|---|